Novel biomarkers for risk stratification of Barrett’s oesophagus associated neoplastic progression–epithelial HMGB1 expression and stromal lymphocytic phenotype

Ross J Porter, Graeme I Murray, Daniel P Price, Russell D Petty, Mairi H McLean* (Corresponding Author)

*Corresponding author for this work

Research output: Contribution to journalArticle

1 Citation (Scopus)
2 Downloads (Pure)

Abstract

Background
The incidence of oesophageal adenocarcinoma is increasing globally. Barrett’s oesophagus (BO) is a pre-malignant condition with no biomarker to risk stratify those at highest risk of dysplasia and malignant transformation.

Methods
Subcellular epithelial protein (HMGB1, p53, RUNX3) expression, alongside expression of CD20, CD4, CD8 and Foxp3 to characterise stromal B lymphocyte, and helper, cytotoxic and regulatory T-lymphocyte cell infiltrate, respectively, was assessed by immunohistochemistry in 218 human tissue samples including normal oesophageal/gastric biopsies (n = 39), BO (non-dysplasia, dysplasia, non-dysplastic background from progressors to dysplasia or cancer, n = 121) and oesophageal adenocarcinoma (n = 58).

Results
There is a dynamic subcellular epithelial expression of HMGB1 (loss of nuclear, emergence of cytoplasmic), associated with epithelial p53 expression and differential immune cell phenotype in oesophageal neoplastic progression. We identify a protein signature and lymphocyte infiltrate in non-dysplastic BO when progressive disease (dysplasia or adenocarcinoma) is present but not histologically represented in the biopsied field. There is a dynamic stromal lymphocytic infiltrate in oesophageal neoplastic progression.

Conclusions
This data reveals novel insights into the microenvironment of BO and progression towards cancer and identifies a novel high-risk biomarker of disease progression to aid surveillance strategies to identify early progression and impact future incidence of oesophageal cancer.
Original languageEnglish
Pages (from-to)545-554
Number of pages11
JournalBritish Journal of Cancer
Volume122
Early online date13 Dec 2019
DOIs
Publication statusPublished - 18 Feb 2020

Keywords

  • Barrett’s oesophagus
  • oesophageal cancer
  • HMGB1
  • lymphocytes
  • biomarker
  • epithelial cell
  • DIAGNOSIS
  • GRADE DYSPLASIA
  • MANAGEMENT
  • PROGNOSIS
  • ADENOCARCINOMA
  • CANCER
  • P53
  • THERAPY
  • BRITISH SOCIETY
  • RADIOFREQUENCY ABLATION

Fingerprint Dive into the research topics of 'Novel biomarkers for risk stratification of Barrett’s oesophagus associated neoplastic progression–epithelial HMGB1 expression and stromal lymphocytic phenotype'. Together they form a unique fingerprint.

Cite this